2018
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, Leming P, Geese WJ, Yoon D, Li A, Brahmer J. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. Journal Of Clinical Oncology 2018, 36: 1675-1684. PMID: 29570421, DOI: 10.1200/jco.2017.77.0412.Peer-Reviewed Original ResearchConceptsLigand 1 expressionOverall survivalAdvanced NSCLCProgressive diseaseOS ratesLung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerLong-term OSPhase III studyProportion of patientsResponse Evaluation CriteriaKaplan-Meier methodLong-term survivorsCell lung cancerEarly phase INivolumab 1Nivolumab treatmentStable diseaseNonsquamous NSCLCAdverse eventsDurable responsesFirst doseFormer smokersIII study
2017
Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.
Liu S, Camidge D, Gettinger S, Giaccone G, Heist R, Hodi F, Ready N, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J. Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study. Journal Of Clinical Oncology 2017, 35: 9092-9092. DOI: 10.1200/jco.2017.35.15_suppl.9092.Peer-Reviewed Original ResearchNon-small cell lung cancerOverall response rateAdverse eventsAnti-programmed death ligand 1 antibodyAdvanced non-small cell lung cancerMetastatic non-small cell lung cancerCommon treatment-related grade 3Terms of ORRConfirmed overall response rateGrade 5 adverse eventsStandard first-line therapyTreatment-related grade 3Death ligand 1 antibodyPhase Ib studyTumor antigen releaseFirst-line therapyPhase III studyPlatinum-based chemotherapyCell lung cancerActionable gene alterationsMulti-arm studiesMultiple tumor typesMedian PFSNSCLC ptsPrior chemo
2015
Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).
Paz-Ares L, Horn L, Borghaei H, Spigel D, Steins M, Ready N, Chow L, Vokes E, Felip E, Holgado E, Barlesi F, Kohlhaeufl M, Rodriguez O, Burgio M, Fayette J, Gettinger S, Harbison C, Dorange C, Finckenstein F, Brahmer J. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2015, 33: lba109-lba109. DOI: 10.1200/jco.2015.33.18_suppl.lba109.Peer-Reviewed Original ResearchNon-squamous cell non-small cell lung cancerPlatinum-based doublet chemotherapyProgression-free survivalSuperior overall survivalPD-L1 expressionOverall survivalDeath-1 immune checkpoint inhibitor antibodyInvestigator-assessed objective response rateGlobal phase III studyImmune checkpoint inhibitor antibodyNon-small cell lung cancerRandomized phase III trialCheckpoint inhibitor antibodyDrug-related AEsObjective response rateSubsequent systemic therapyTrials of nivolumabPhase III studyPhase III trialsCell lung cancerTyrosine kinase inhibitorsQuality of lifeDoublet chemotherapyIII studyIII trials
2013
Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK -positive non-small cell lung cancer (NSCLC).
Solomon B, Gettinger S, Riely G, Gadgeel S, Nokihara H, Han J, Hida T, Satouchi M, Baldini E, Siena S, Yamamoto N, Horn L, Tassell V, Polli A, Camidge D. Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK -positive non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 8105-8105. DOI: 10.1200/jco.2013.31.15_suppl.8105.Peer-Reviewed Original ResearchNon-small cell lung cancerMedian PFSPFS ratesSubgroup analysisSuperior efficacyAdvanced ALK-positive non-small cell lung cancerALK-positive non-small cell lung cancerManageable side-effect profilePrior platinum-based regimenStage IIIB/IVCausality adverse eventsMedian treatment durationPlatinum-based regimenSafety of crizotinibIIIB/IVPhase III studySide effect profileCell lung cancerIndependent radiologic reviewPEM patientsPo bidPROFILE 1007Crizotinib treatmentCare chemotherapyData cutoffA phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC).
Gettinger S, Brahmer J, Rizvi N, Ready N, Chow L, Antonia S, Buyse M, Jassem J, Finckenstein F, Crinò L, Lynch T. A phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: tps8121-tps8121. DOI: 10.1200/jco.2013.31.15_suppl.tps8121.Peer-Reviewed Original ResearchNon-squamous NSCLCOverall survivalTyrosine kinase inhibitorsPD-L1Maintenance therapyAdvanced diseaseLung cancerDisease progressionPlatinum-based doublet chemotherapyRecurrent non-squamous NSCLCPhase III comparative studyMedian overall survivalObjective response ratePhase III studyProgression-free survivalPhase 1 studyCell lung cancerDurable antitumor activityPD-1 receptorImmune checkpoint receptorsT cell activationDoublet chemotherapyNSCLC ptsOS benefitUnacceptable toxicity
2008
Targeted Therapy in Advanced Non-Small-Cell Lung Cancer
Gettinger S. Targeted Therapy in Advanced Non-Small-Cell Lung Cancer. Seminars In Respiratory And Critical Care Medicine 2008, 29: 291-301. PMID: 18506667, DOI: 10.1055/s-2008-1076749.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzenesulfonatesBevacizumabCarcinoma, Non-Small-Cell LungDrug Delivery SystemsEpidermal Growth FactorErlotinib HydrochlorideHumansIndolesLung NeoplasmsNiacinamidePhenylurea CompoundsPiperidinesProtein Kinase InhibitorsPyridinesPyrrolesQuinazolinesSignal TransductionSorafenibSunitinibTreatment OutcomeVascular Endothelial Growth Factor AConceptsPhase II trialLung cancerEpidermal growth factor receptorII trialEGFR inhibitorsSmall molecule inhibitorsAdvanced non-small cell lung cancerNon-small cell lung cancerStandard first-line chemotherapyVascular endothelial growth factor (VEGF) pathwayEndothelial growth factor pathwayCancer cell pathwaysStandard salvage chemotherapyFirst-line chemotherapyPhase III studyPhase III trialsCell lung cancerSignificant survival advantageEGFR gene mutationsLeast equivalent activityVEGF receptor tyrosine kinasesCancer cell proliferationGrowth factor pathwaysGrowth factor receptorSalvage chemotherapy